Daily Stock List
Tengion, Inc. (TNGN)
TheStockfather, StreetInsider, Stock Fortune Teller, MadPennyStocks, StockEgg, StockRich, PennyInvest, CoolPennyStocks, PennyStockVille, BullRally, and HotOTC reported earlier on Tengion, Inc. (TNGN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Winston-Salem, North Carolina, Tengion, Inc. is a clinical-stage regenerative medicine company. Tengion concentrates on discovering and developing regenerative products. The Company is focusing their resources on two large patient populations where the standard of care entails significant costs, involves complicated procedures, and imposes quality of life challenges. Tengion's shares trade on the OTCQB.
The Company is working on developing their Organ Regeneration Platform™. This platform is to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Using their Organ Regeneration Platform™, Tengion is pioneering the development of products consisting of a patient's own (autologous) living cells, with or without a biocompatible material component, which undergo implantation into the body to engraft into, repair, regenerate, or replace a damaged tissue or organ.
Tengion's most advanced product candidate is the Neo-Urinary Conduit™. An initial clinical trial is ongoing for this product candidate. The Neo-Urinary Conduit™ is an autologous implant intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal.
The Company's lead preclinical candidate is the Neo-Kidney Augment™. The design of this is to prevent or delay dialysis kidney transplantation through increasing renal function in patients with advanced chronic kidney disease. Tengion has global rights to their product candidates.
Last Friday, Tengion announced the unrelated deaths of two patients enrolled in the ongoing Phase 1 clinical trial of the Company's most advanced product candidate, the Neo-Urinary Conduit, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). Tengion successfully implanted the fifth patient in the ongoing Phase 1 trial in June 2012 and the patient's Neo-Urinary Conduit is currently functioning well with normal renal function.
The fourth patient enrolled in the Phase 1 trial was implanted with the Neo-Urinary Conduit in February of this year. The death of the fourth patient was associated with widespread metastasis of his bladder cancer. Until the time of his death, the patient's Neo-Urinary Conduit functioned well and he maintained normal renal function.
Tengion, Inc. (TNGN), closed Wednesday's trading session at $1.10, up 1.85%, on 3,125 volume with 10. The average volume for the last 60 days is 12,007 and the stock's 52-week low/high is $0.87/$2.25.
AdvanSource Biomaterials Corp. (ASNB)
Nebula Stocks reported previously on AdvanSource Biomaterials Corp. (ASNB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Based in Wilmington, Massachusetts, AdvanSource Biomaterials Corp. manufactures advanced polymer materials providing critical characteristics in medical device design and development. These biomaterials are used in devices designed for treating a wide spectrum of anatomical sites and disease states. The Company's business model takes advantage of their proprietary materials science technology and manufacturing expertise to expand their product sales and royalty and license fee income. AdvanSource Biomaterials lists on the OTCQB.
The Company's expertise lies in the synthesis and formulation of polymeric materials with an extensive range of physical and chemical properties. These materials possess unique characteristics such as biocompatibility, biodurability, and can be tailored for specific properties such as lubricity and antimicrobial formats. Their materials include polycarbonate and polyether based polyurethanes, liquid polymers, hydrophilic solutions and extrudable grade materials, echogenic coatings, antimicrobial materials, dissimilar material bonding agents, colorant technologies, and an assortment of additional TPU's and elastomers. Services including prototype coating and colorant technologies are also available.
AdvanSource's leading edge technology, with products including ChronoFlex, HydroMed, and HydroThane, has undergone development to overcome a broad array of design and functional challenges. This is from the need for dimensional stability, ease of manufacturability, and demanding physical properties, to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion.
Specializing in polyurethane technologies, AdvanSource Biomaterials offers a variety of material formats for use in long and short-term implants and disposable products. The Company's materials can be customized to meet a wide range of mechanical properties with product extensions to include radiopaque.
AdvanSource Biomaterials manufactures and sells their custom polymers under the trade names ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, and PolyBlend. Conventional polymers are susceptible to degradation resulting in catastrophic failure of long-term implantable devices such as pacemaker leads. The design of ChronoFlex and ChronoThane polymers are to overcome such degradation and reduce the incidents of infections associated with invasive devices.
The Company manufactures and sells their proprietary HydroThane polymers to medical device manufacturers that are evaluating HydroThane for use in their products. HydroThane is a thermoplastic, water-absorbing, polyurethane elastomer. AdvanSource's PolyBlend is a family of exceptionally soft, aromatic polyurethane elastomeric alloys. These can be used as a substitute for natural rubber or latex in many applications.
AdvanSource Biomaterials Corp. (ASNB), closed Wednesday's session at $0.42, even for the day, on 2,500 volume with 1 trade. The average volume for the last 60 days is 34,096 and the stock's 52-week low/high is $0.0101/$0.1318.
Conolog Corp. (CNLG)
Lebed.biz and OTC Picks reported previously on Conolog Corp. (CNLG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Conolog Corp. designs, produces, and distributes small electronic and electromagnetic components and sub-assemblies primarily to power companies and military in the U.S. Established in 1968; the Company is a pioneer in Hi-Reliability Communication Equipment and components. Conolog emerged as a major supplier of Filters, Oscillators, and Frequency Discriminators for manufacturers of telemetry systems for Electric, Transit, Renewable and Water/Wastewater utilities. In 1980, the Company acquired Iniven, an electronics manufacturer making FSK (frequency shift keyed) audio communication equipment. Conolog has their corporate headquarters in Somerville, New Jersey.
Conolog offers transducers; digital signal processing systems and electromagnetic wave filters for differentiation among audio and radio frequencies; and audio transmitters and modulators for the transmission of electrical signals obtained from transducers, data generated in electronic code form, or by computers over telephone lines, microwave circuits, or satellites. They also offer audio receivers and demodulators. In addition, the Company offers magnetic networks devices; analog transmitters and receivers; and multiplexer supervisory controls that enable callers with high volumes of supervisory data to transmit on fewer phone lines.
Their Iniven division continues the Conolog tradition of solving complex communication challenges for electric utilities, fiber optic communication service providers and the U.S. military. Iniven is an innovator in protective relaying and monitoring solutions; they engineer custom-configured communication equipment ranging from fully digital high speed transfer trip communications for use in electric power transmission pilot protection schemes (PDR-2000, GlowWorm) and active control of fiber network communication (Fidra).
GlowWorm (Passive Fiber Signal Monitoring) is for those users who wish to monitor and protect their fiber-optic communication network, without having to reconfigure it. Fidra (Multifunction relay-to-relay fiber optic control and monitoring) is an industry first in fiber-optic protective relaying communication. Fidra enables active control of fiber optic communication, so a user can easily manage any type of fiber-optics signaling for operations and testing.
This past June, the Iniven division of Conolog announced the first sales contract for the new Fidra. Under the agreement, Iniven will manufacture, deploy and support Fidra units to Southern Company, one of the largest providers of electricity in the nation, serving more than four million customers across the southern United States.
Conolog Corp. (CNLG), closed Wednesday's session at $0.08, even for the day. The average volume for the last 60 days is 9,619 and the stock's 52-week low/high is $0.0501/$0.119.
Klondex Mines Ltd. (KDX.TO)
Vantage Wire and AllPennyStocks reported previously on Klondex Mines Ltd. (KDX.TO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Based in Vancouver, British Columbia, Klondex Mines Ltd. engages in owning, acquiring, exploiting, exploring, developing and evaluating mineral properties. The Company either joint ventures or develops these properties further disposing of them upon the completion of an evaluation. Currently, Klondex Mines is focusing on the exploration and development of their 100 percent owned Fire Creek gold deposit in North Central Nevada. The Company's shares trade on the Toronto Stock Exchange and on the OTCQX International under the symbol KLNDF.
The Fire Creek deposit is a gold mining prospect in a region of prolific gold production. The deposit is near power, transportation, mining infrastructure and a number of milling facilities. Fire Creek is strategically located between the past producing Mule Canyon Mine to the north and the world-class Pipeline and Cortez gold deposits to the south. The property consists of 11,208 acres (17.5 square miles).
Klondex Mines' secondary focus is acquiring, exploring and developing other gold and silver properties in Nevada. Currently, the Company has three other gold exploration properties, and they review and consider other projects for inclusion as well. One of the properties is the Reef Project. The 8 Reef claims in the Fairchild district of Churchill County are in the heart of an old silver mining district with production dating back to the late 19th century. Anomalous gold and silver have been detected along a siliceous reef that runs approximately half a mile.
Klondex also has 42 claims at Hot Springs Point, approximately six miles east of the town of Crescent Valley. The Company also holds a 66.66 percent interest in 48 claims in the Schroeder Mountain quadrangle. The property is on three separate sections located approximately three miles northeast of Newmont's Gold Quarry mine, and 1.5 miles east of the old Queen Anne mine in the heart of the Carlin Trend.
Last month, Klondex Mines reported several intercepts of gold mineralization for the recently completed surface drilling program at their Fire Creek gold project in Lander County, Nevada. A total of 2,465 meters (8,086 feet) of core were drilled to extend ten holes that had been pre-collared with reverse circulation (RC) drilling.
All ten core holes encountered gold mineralization, with the best results including 2,910 g/t (85 oz/ton) gold over 1.5 meters (4.8 feet) in hole FC12-11S (the same intercept also contained 5,960 g/t (174 oz/ton) silver); 97.9 g/t (2.9 oz/ton) gold over 0.4 meters (1.7 feet) in hole FC12-13S, and 57.7 g/t (1.7 oz/ton) gold over 1.1 meters (3.7 feet) in hole FC12-21S.
Klondex Mines Ltd. (KDX.TO), closed Wednesday's trading session at $1.45, even for the day, on 12,700 volume. The stock's 52-week low/high is $1.12/$2.88.
Quture International, Inc. (QUTR)
We are highlighting Quture International, Inc. (QUTR), here at the QualityStocks Daily Newsletter.
Quture International, Inc. is an emerging growth company that lists on the OTCQB. They are positioning to become the leading clinical knowledge company in the world. Their core competence is clinical performance enhancement to achieve optimal patient outcomes. Quture International's products and technology-based solutions electronically integrate clinical data that will significantly exceed compliance requirements. The Company is based in Daytona Beach, Florida.
Quture consists of subsidiaries in North America and Europe for the operations of their software technology solutions; plans for a "beyond data" consulting and knowledge applications company, as well as plans for a personalized, proactive and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which Quture intends to become the largest medical and health exchange in the world.
Quture International owns two fully developed and tested products. Both of these are being migrated from a Microsoft technology platform onto the InterSystems technology platform, with the Cache object-oriented database serving as the foundation for each and providing a unified Quture database to be called the "Qualytx" database.
Real-time clinical data is captured electronically from multiple vendor disparate databases using the Ensemble interface engine and aggregated into the Qualytx database.
The DeepSee dashboard and Zen report writer technology are functionalities existing in the InterSystems Ensemble Enterprise suite of products. The Quture products on the InterSystems platform are QualOptima (clinical performance measurement with analytics) and QSurg (surgery center electronic medical record (EMR) with a simplified QualOptima (QuOp) performance analytics application embedded).
Quture's intention is to introduce their QualOptima performance measurement product into the market after completion of a formal "clinical trial" at the University of Miami, Miller School of Medicine and Jackson Memorial Hospital. The proof of concept Phase I portion of that demonstration project has been successfully completed based on sample data and to the satisfaction of Quture and InterSystems. The Company anticipates marketing and sales of the QSurg product will follow introduction of the QualOptima product, projected by Quture to begin six months after the beginning of marketing and sales of QualOptima.
Quture International, Inc. (QUTR), closed Wednesday's trading session at $0.0075, up 17.19%, on 344,500 volume with 7 trades. The average volume for the last 60 days is 787,440 and the stock's 52-week low/high is $0.0028/$0.034.
Oremex Gold, Inc. (OAU.V)
Today we are highlighting Oremex Gold, Inc. (OAU.V), here at the QualityStocks Daily Newsletter.
Oremex Gold, Inc. is a gold exploration and development company created from the spinout of gold assets owned by Oremex Silver, Inc. (previously Oremex Resources, Inc.) in 2011. The Company has a portfolio of 100 percent owned gold properties in prolific mining regions of Mexico. Oremex Gold's shares trade on the TSX Venture Exchange. The Company has their headquarters in Toronto, Ontario.
Oremex Gold's two main projects are Cerro del Oro, located in the historic Melchor Ocampo gold district and Santa Catarina, located in the prolific Sierra Rosario gold belt. Cerro del Oro consists of two concessions totaling 78.9 hectares located in northern Zacatecas state. The concessions cover the core of the historical Melchor Ocampo gold mining district. Santa Catarina consists of two mineral concessions covering 142 hectares.
Oremex also has their San Lucas project. It consists of 18 mineral concessions covering 925.32 hectares. In addition, the Company has their Maco project. Maco is in the early grass roots stage of exploration. It consists of a single claim covering 1,500 hectares. Furthermore, Oremex has their Navidad project. This is also in the early grass roots stage of exploration. It consists of one mineral concession covering approximately 134 hectares.
This month, Oremex Gold announced that an interested third party in Mexico is alleging ownership of two concessions totaling 78.9 hectares in the Melchor Ocampo gold mining district, Zacatecas state, Mexico, comprising the Company's Cerro del Oro (Gold Hill) project.
Acquisition of the Cerro del Oro concessions by Oremex Gold's wholly owned subsidiary, Minera Tres Diamantes, S. de R.L. de C.V., from Minera Mantos, S. de R.L. de C.V., a wholly-owned subsidiary of Oremex Silver, was previously announced on February 23, 2012. Before acquisition by the Company, the Cerro del Oro concessions had been subject to a court process to determine the legal owner of the property. The Company acquired the concessions only after it had been advised that the legal ownership matter had been favorably resolved and the final court decision in the process was non-appealable.
Oremex Gold has engaged, and is working with, various legal and other advisors in the jurisdiction to refute any challenge to the legal ownership of the Cerro del Oro concessions. Until this issue is resolved, they do not intend to undertake any further exploration work on the Cerro del Oro concessions or release results in connection with exploration work on the concessions.
Oremex Gold, Inc. (OAU.V), closed Wednesday's trading session at $0.075, even for the day. The stock's 52-week low/high is $0.05/$0.16.
Implant Sciences Corp. (IMSC)
Corporate Profile Team reported earlier on Implant Sciences Corp. (IMSC), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Implant Sciences Corp. is a high technology supplier of systems and sensors. They manufacture and sell sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in their commercial explosive and narcotics trace detection systems, which ship to a growing number of locations domestically and globally. Founded in 1984, Implant Sciences has their headquarters in Wilmington, Massachusetts.
Implant Sciences' products undergo deployment worldwide to enhance the safety and security of their customers in areas such as aviation security, force protection, subway security, customs and immigration, cargo security, critical infrastructure protection, ports and tunnels security, and VIP protection.
The Company develops and manufactures explosive trace detection sensors and systems capable of detecting minute amounts of a broad array of military, commercial, and homemade explosives. Their patented technologies provide unique screening capabilities to extend and improve counter-terrorist and homeland security efforts.
Their QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation. Implant Sciences' QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a broad spectrum of military, commercial, and homemade explosives, as well as drugs.
Last Friday, Implant Sciences provided an update regarding the air cargo screening qualification testing process for the Company's QS-B220 explosives and narcotics trace detector by the Transportation Security Laboratory (TSL), the testing body of the Transportation Security Administration (TSA).
Mr. Glenn Bolduc, President and CEO of Implant Sciences, stated, "As of today, the QS-B220 is with the TSL as part of the independent testing and evaluation process. Independent testing began in early October, after we were notified that we had successfully completed certification readiness. The qualification testing is, by design, an extensive and rigorous process that requires several weeks to complete. We continue to enjoy a strong working relationship with TSL, and have every reason to believe that we will successfully achieve qualification for our QS-B220 trace detector in the near term."
Implant Sciences Corp. (IMSC), closed Wednesday's session at $1.22, down 1.61%, on 152,938 volume. The average volume for the last 60 days is 264,977 and the stock's 52-week low/high is $0.48/$1.84.
Casablanca Mining Ltd. (CUAU)
PickPennyStocks, Michael Stone, OTCtipReporter, PennyStockScholar, SmallCapInvestorDaily, Growing Stocks Reports, Research Driven Alerts, Stockdigest Report, PennyTrader, The Stock Psycho, and Top Gun reported this month on Casablanca Mining Ltd. (CUAU), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Santee, California, Casablanca Mining Ltd. engages in the acquisition, exploration, development, and operation of precious metal properties in South America. They accomplish this through their wholly owned subsidiary Santa Teresa Minerals, S.A. Their gold and copper mining operations are based near Santiago, Chile. Casablanca Mining lists on the OTCQX U.S.
The Company's Santa Teresa Minerals currently has, directly and indirectly through various equity interests, mining rights in 80 different mining and mineral exploration properties. These include gold, copper and copper sulfate. Santa Teresa Minerals has mining rights in exploration projects, "Free Gold", the "Casuto Project," consisting of Los Azules 1-3, Tauro 1-6, Los Chipi 1-22, and the "New Gold Project," consisting of Los Pinos 1-30 and Teresita 1-20.
Santa Teresa Minerals also owns an equity position of Bluestone S.A., a copper sulfate production project that owns the Anica Copper Mines. In addition, Santa Teresa Minerals owns a 60 percent equity position in a company with the rights to an innovative mining technology that extracts gold, silver, and copper from raw mining materials using a proprietary and patented electrolysis method of electromining.
Today, Casablanca Mining announced that their wholly owned subsidiary, Santa Teresa Minerals, provided the Company with results of their test mining at the Las Dichas gold property in Chile. The Las Dichas property is a joint venture partnership between the Company and the mineral landowner. Gold production from Las Dichas is split equally from the onsite alluvial process. The Las Dichas gold property utilizes their mobile processing unit, which facilitates washing of alluvial gold deposits.
In areas with high concentrations of alluvial gold, Casablanca Mining can deploy their mobile processing unit to take immediate advantage of accessible ore deposits with no entry costs and a 50 percent allocation of produced gold. Company Management is reviewing the initial months of production and will determine if they will keep their mobile processing at Las Dichas or relocate to a more profitable area.
Casablanca Mining Ltd. (CUAU), closed Wednesday's trading at $0.3175, down 20.62%, on 686,998 volume with 189 trades. The average volume for the last 60 days is 173,879 and the stock's 52-week low/high is $0.051/$7.20.
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.95, up 33.80%, on 1,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 674, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring
VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund
VistaGen CEO Issues Update Letter to Stockholders
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.09, up 20.00%, on 3,333 volume with 1 trade. The stock’s average daily volume over the past 60 days is 9,115, and its 52-week low/high is $0.01/$0.51.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com Provides Preliminary Financial Results for the Third Quarter of 2012
Loans4Less.com, Inc. New Audio Interview With Chairman and CEO Steven M. Hershman
Loans4Less.com, Inc. Announces Engagement of QualityStocks Investor Relations Services.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $4.50, up 7.14%, on 39,096 volume with 48 trades. The stock’s average daily volume over the past 60 days is 42,572, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.25, up 3.73%, on 57,150 volume with 30 trades. The stock’s average daily volume over the past 60 days is 57,150, and its 52-week low/high is $0.21/$0.705.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp's Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs
International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
International Stem Cell Corp to Participate in Upcoming Investor Conference
A recent study and evaluation of mental health specifically addressed conditions in the province of Ontario in Canada, but a good argument can be made that many of the conditions it uncovered likely parallel those in other parts of Canada and in the United States. As such, it offers an idea of the potential market for the kind of mental health services offered by GreeneStone Healthcare, an Ontario-based healthcare provider seeking to expand its operations to meet a growing need in the areas of addiction, eating disorders, and other areas of mental health.
In particular, the evaluation emphasized the wide-ranging scope of the mental health problem, indicating that most people in Ontario are affected over time, either directly or indirectly, by mental illness and addiction issues, and that fully one in five Canadians are affected each and every year. The study suggests that associated problems often begin at a young age, but can continue throughout the person’s life, ultimately affecting their social connections as well as education and workforce participation. Mental health can, in fact, be the predominant health related factor affecting a person’s life, even though it often goes unrecognized.
Although major physical diseases tend to result in a greater actual loss of life, mental illness, such as depression, bipolar disorder, alcohol and drug addiction, is foremost when it comes to years lost to reduced functioning. The study says that, for Ontario, the burden of mental illness and addictions is 50% greater than all forms of cancer put together. The cost of depression alone, in terms of reduced functioning, exceeds the combined burden of lung, colorectal, breast, and prostate cancer. But mental health issues can also be life threatening, with alcohol use disorders responsible for more deaths than some cancers and infectious diseases.
The study concludes that, although effective treatments exist for mental illness and addiction, only a small proportion of affected individuals receive them. Given the extent of the problem, there is clearly a strong unmet need for the application of preventative and treatment methodologies. GreeneStone recognizes the need, and is actively growing through a “build and buy” strategy, and aims to ramp up revenue from $7 million to nearly $90 million in the coming years.
For additional information, visit the company’s websites at www.GreeneStoneClinic.com and www.GreeneStoneInvestor.com
GlobalWise Investments, through its wholly-owned subsidiary, Intellinetics, offers advanced cloud-based Enterprise Content Management (ECM) solutions to commercial and government operations in a way that allows secure authorized access to critical documents and information from anywhere in the world, and any time of day or night. The bottom line for organizational clients is that previously buried information now becomes available to whoever needs it, whenever they need it, regardless of where they are, providing a major operational advantage. For GlobalWise, the unique combination of advanced ECM software and cloud technology gives them a foot in both the ECM industry and cloud computing space, representing two significant growth industries.
The ECM industry, designed to greatly facilitate the capture, storage, and access of all types of documents, is expected to grow by over 10% annually, and exceed $5.7 billion by 2014. The rapidly growing volume of documents and information that organizations must now process on a daily basis is clogging operational arteries, creating a drain on resources. ECM, which GlobalWise now integrates with existing document scanning and copying functions, makes the capturing and retrieval of this information easy, positively affecting all operational aspects.
The adoption of cloud computing is expected to maintain a compound annual growth rate of over 25%. Of special significance is the Tier 3 and Tier 4 market (small to mid-size business) that GlobalWise targets, an important part of the $149 billion overall business software and services industry. The GlobalWise flagship platform, Intellivue, represents a new industry benchmark, combining advanced virtualization and automated content management with an open and service oriented architecture using Web services. Cloud processing is the only way that offers increasingly diversified, scattered, and complex organizations the ability to access the information they need in a totally flexible way.
To learn more about GlobalWise and its software solutions, visit www.GlobalWiseInvestments.com
Uranium Resources, which has in-situ recovered (ISR) over 8M lbs of uranium out of the earth since the company’s inception in the rich Texas Gulf Coast uranium region back in 1977 (now holding four major properties, while controlling two evaluation projects in the region), reported positive groundwater safety findings today on their Church Rock Section 8 project (McKinley County, New Mexico), drawing on the extensive material contained in the Section 8 / Navajo-Gallup Groundwater Report and Conjunctive Use Evaluation study.
This study, which was a joint effort between the City of Gallup and the Navajo Nation authorities, looked at the environmental impact of ISR operations at the project with respect to existing water wells for the respective entities, in addition to those wells serving Fort Wingate and Rhoboth. Conclusively, the evaluation shows that not only is the ISR methodology extremely safe and environmentally friendly, but that no discernable risk exists for groundwater contamination.
This is a glowing report that spells a big green light for URRE’s Church Rock S8 project and it details clearly that there should be no complications for future mining operations either, something which allows the interested parties to rest easy, secure in the knowledge that the wells and the Navajo-Gallup Water Supply Project will remain untainted. The long-term results are always important in uranium mining and it is indeed reassuring to have a good future vector for extraction mapped out in the study. With future wells not being a problem, the site could quickly evolve as the company’s major flagship project in New Mexico.
The company currently holds some 206k acres (152.9M lbs of in-place mineralized uranium material) in New Mexico, with a 1M lbs/year production license. After accumulating vast amounts of data in the form of assay certificates, drill hole logs, maps, and technical reports over the last two decades, URRE is well-positioned with a variety of properties like Church Rock to really make a name for itself in New Mexico. New Mexico and Texas form a strong resource base for URRE and with this kind of undeveloped uranium potential under the company’s thumb, the possibilities for partnering are increasingly choice as the asset base is expanded, especially with larger firms that lack access to new resource targets, or with junior’s who lack the logistical capacity and know-how of a URRE.
Senior VP of Health, Safety, and Environmental Standards for URRE, Mark S. Pelizza, was quite pleased with the results, confirming to shareholders that the satisfaction of both chief parties via this joint effort roundly substantiates the company’s own analysis. Church Rock looks safe to mine and the company’s ISR proficiency will prove to be not only ideal for extraction, but extremely delicate. Of course this is one of the benefits of ISR in general and URRE is a master of the technique, which uses injection and recovery to literally drink the uranium right out of the ore body, leaving the rock undistributed.
Pelizza called the jointly developed study a “solid step forward” towards satisfying the concerns of the Navajo Nation, with whom URRE is still in talks and he underscored how the study was essentially over-designed to yield high tolerances for safety.
The Navajo Nation and the City of Gallup pegged veteran engineering, geoscience, and hydrology firm, B. Stephens and Associates, Inc., to handle the report preparation, and it is important to note that the groundwater migration rates and proximity of supply wells were both calculated as being well above projections. In addition to this over-design characteristic, employed out of circumspection and to give the interested parties all the more reason to okay the project, natural dilutive geochemical processes which would remove the element over time were also disregarded, resulting in truly high-fidelity assertions. Given this over-design of the parameterization, in combination with the positive final safety results, investors will be keen to see just how fast uranium development activity accelerates for URRE at Church Rock.
With over 430 operating reactors on earth today, chewing up over 177M lbs of yellowcake each year (36% over last year’s production), the fundamental dynamics are clear for nuclear. Four to six new reactors may come online domestically by 2020 after a three-decade stint of depressed construction, while abroad in places like China, they have 25 being built, including some of the most advanced in the world. Yes, the future for nuclear power is indisputable and globally the market is quite large for the kind of high-quality yellowcake URRE will be pulling out of the ground in New Mexico and Texas, giving shareholders solid price horizons and investors a hot play with some serious upside potential.
For more information on Uranium Resources, visit www.UraniumResources.com
CounterPath, a global provider of personal computer and mobile application software as well as gateway server software products, announced today that it will enter into a strategic license royalty agreement with Nippon Telegraph and Telephone (NTT) Software Corporation that enables Japanese enterprises to provide unified communications (UC) and fixed-mobile convergence (FMC) services to their customers’ mobile workers, telecommuters, and business travelers. CounterPath’s Bria mobile and Client Configuration Server (CCS) will be integrated in unison to deliver innovative options for the management of communications spending while maximizing employee productivity and responsiveness.
The agreement stipulates that NTT Software Corporation will leverage the award-winning Bria mobile softphone applications with the Client Configuration Server to give enterprise customers the ability to extend VoIP and IP PBX to their current mobile devices. By utilizing this solution, employees can use their own devices and Bria’s platform diversity to deliver services across the world’s most widely used smartphone platforms.
Bria provides high-quality voice calls over 3G, 4G, and Wi-Fi by using industry standards and proven multimedia technology. Bria can also enable least-cost routing by switching between mobile and Wi-Fi data networks on the fly. This capability gives enterprise customers more flexibility in managing their telecom spending.
“Together with NTT Software we are focused on enabling the mobile workforce to be connected any place, any time,” said Todd Carothers, CounterPath Executive Vice President of Sales and Marketing. “With Bria and the Client Configuration Server, NTT Software’s customers’ will have a fast, cost-effective and uncomplicated way to extend services to nearly any employee with an iOS or Android smartphone. As part of the world’s largest global IT and telecommunications services company, NTT Software is an important partner for CounterPath and we are excited to grow this important channel within Japan.”
For further information, please visit www.counterpath.com
Today's Top 3
Investor News Source
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund